BTG plc (LON:BTG) issued its quarterly earnings results on Tuesday. The company reported GBX 21 ($0.28) EPS for the quarter, hitting the consensus estimate of GBX 21 ($0.28), Bloomberg Earnings reports. BTG plc had a net margin of 7.26% and a return on equity of 4.33%. The firm had revenue of GBX 3,413 billion for the quarter.
BTG plc (LON BTG) traded up GBX 7 ($0.09) during trading hours on Thursday, reaching GBX 710.50 ($9.34). The company’s stock had a trading volume of 416,732 shares, compared to its average volume of 649,511. BTG plc has a 52 week low of GBX 528.36 ($6.95) and a 52 week high of GBX 779 ($10.25).
Several brokerages have commented on BTG. Deutsche Bank AG reiterated a “buy” rating and issued a GBX 775 ($10.19) price target on shares of BTG plc in a research report on Tuesday, November 7th. Peel Hunt restated a “hold” rating and set a GBX 680 ($8.94) price objective on shares of BTG plc in a report on Monday, November 6th. J P Morgan Chase & Co restated a “neutral” rating on shares of BTG plc in a report on Friday, October 6th. Numis Securities Ltd restated a “buy” rating and set a GBX 900 ($11.84) price objective on shares of BTG plc in a report on Wednesday, August 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 800 ($10.52) price objective on shares of BTG plc in a report on Wednesday, August 30th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. BTG plc currently has a consensus rating of “Buy” and an average price target of GBX 779.13 ($10.25).
ILLEGAL ACTIVITY WARNING: This report was reported by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://baseballnewssource.com/markets/btg-plc-btg-announces-quarterly-earnings-results/1780021.html.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with our FREE daily email newsletter.